I’ve written several times about MS and the flu. I’ve always encouraged people to get an annual flu shot, but I know some people, for whatever reasons, don’t get one. I know I’ll never convince some of you of the benefits of this shot, no matter how much…
The MS Wire — Ed Tobias
People say to write what you know and Ed Tobias knows about MS. He’s lived with the illness since 1980, when he was 32 years old. Ed’s a retired, award-winning broadcast journalist and his column combines his four decades of MS experiences with news and comments about the latest in the MS community. In addition to writing his column, Ed is one of the patient moderators on the MS News Today Facebook, Twitter, and Instagram sites. He’s also the author of “The Multiple Sclerosis Toolbox: Hints and Tips for Living with M.S.” Ed and his wife split their time between the Washington, D.C. suburbs and Florida’s Gulf Coast, trying to follow the sun.
Featured Post
This is my 823rd column for Multiple Sclerosis News Today. It is also my last. Over the past seven and a half years, I’ve written about multiple sclerosis (MS) fatigue and frustration, about treatments and travel, about neurologists (good and bad), stress,…
By now you may have heard that actress Selma Blair has revealed that she has multiple sclerosis (MS). That took a lot of guts. Those of us who share her diagnosis might learn a few things from what she’s shared and how she’s shared it. Blair may be…
Stanford Researchers Open Medical Cannabis Company with Oral Therapy for MS Pain, Spasticity as Initial Goal Let’s be clear up front. There’s no indication that you’ll be able to buy a cannabis pill from this company anytime soon — or ever. The company’s website says that testing…
“Deceptive” and “false” are two words used by the U.S. Federal Trade Commission (FTC) to describe marketing claims by two stem cell treatment clinics in California. According to an FTC complaint, the clinics had been advertising that they were using amniotic stem cell therapy to successfully treat serious diseases, including…
Flying isn’t what it used to be, as everyone who’s taken a flight in the past 15 years or so knows. Flyers with disabilities can have a particularly challenging time dealing with airports, airlines, and aircraft. Airports are crowded and stretch forever. Airplanes are crowded, their seats are small,…
Please forgive me, but I’m too tired to write tonight. My wife had surgery last week, so I’ve been doing a couple of things that I haven’t done much in the 42 years since our wedding: shopping and cooking. (Well, making Harris Teeter ready-to-heat meals, that is. For…
People with multiple sclerosis (MS) rarely get the opportunity to talk to the people who design their medications. But a new collaboration is providing that opportunity to a few of us. The Accelerated Cure Project for Multiple Sclerosis (ACP) and pharmaceutical manufacturer EMD Serono have begun working together…
Is getting from home to a healthcare appointment a pain in the butt for you? Do you have to search for someone to take you? Do you haul yourself into your car and hope that you can find a nearby parking spot? Is public transportation impossible to find where…
Lower Fatigue Reported by MS Patients After aHSCT in Canadian Study Fatigue affects 90 percent of people with MS. It certainly impacts my life. This study, though very small, reports a 36 percent reduction in the median modified Fatigue Impact Scale (mFIS) score three years after autologous…
Many of us have received help to pay for our MS medications. Now there’s a chance that assistance could be threatened. A recent article in the The Wall Street Journal reports that U.S. government prosecutors are looking into whether some pharmaceutical companies’ patient assistance programs are on the wrong…
We all know how difficult it can be to find an accessible parking spot — one that allows us to park and get from our car to where we’re going with a minimum number of steps. There aren’t many of these spots in most parking lots, and sometimes the…
Often-overlooked MRI Signal May Aid in Early Diagnosis of MS, Other Brain Conditions, Study Suggests A part of an MRI scan that radiologists call a “background signal” is what’s being looked at. It’s usually ignored because the signal doesn’t seem to change even when a patient is…
Ocrevus (ocrelizumab) is a serious disease-modifying therapy. It has the potential to deliver a major blow to a patient’s MS, but it also carries the possibility of severe side effects. The protocol for Ocrevus requires different doses on different infusion dates, following a specific treatment schedule. It’s also…
I never thought I’d want a wearable internet device until I got an Apple Watch for my birthday. One of its neat apps tracks the laps that I swim, the steps that I (try to) take, and my pulse rate. The watch can even link up with some high-tech…
Phase 3 Trial in the UK Soon to Test Statin, Simvastatin, in Slowing SPMS Progression I’ve taken a statin medication for years to keep my cholesterol in check. Now, a study is getting underway to see if one statin pill can also be used to treat MS. It’s particularly…
Is quadrupling the price of a medication “moral”? One pharmaceutical CEO not only thinks so, but he also says it’s a “moral requirement.” The medication is liquid nitrofurantoin, an antibiotic mixture that’s primarily used to treat bladder and urinary tract infections. Since UTIs can be a problem for people…
Editor’s note: Shortly after this column was published, Mylan pharmaceuticals announced it will begin distributing Dalfampridine Extended-Release Tablets, 10 mg, the authorized generic version of Acorda’s Ampyra. There’s been no word, yet, on what it will cost or how soon the generic will become available in pharmacies. A few…
The start of flu season here in the United States is just a few weeks away. It’s time for my wife and me to get our flu shots, just as we have for as long as I can remember. My neurologist and our primary care physician both recommend the…
How B-cells Work to Promote T-cell Attacks on Myelin That Lead to MS Detailed in Study I keep a close eye on reports about B-cells and T-cells because they’re the targets of Lemtrada, which is my current disease-modifying therapy. (The DMT Ocrevus targets B-cells alone). So, this…
Ocrevus, a disease-modifying MS treatment that’s only been on the market a little less than 18 months, appears poised to be a cash cow for its maker, Genentech. The research firm Spherix Global Insights, which analyzes trends in the pharmaceutical industry, predicts that Ocrevus is “poised to…
Explore More Columns
Discussion
Discussion
Discussion